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I
n its effort to develop worldwide standards of trial registration, the World Health Organization (WHO) has formally launched its International Clinical Trials Registry Platform (ICTRP) project. The project is "taking the lead in setting international norms and standards for trial registration and reporting" [1] .
As part of the project, on 25-27 April 2005, the WHO organized a technical consultation on clinical trial registration standards. The outcome of this consultation included a defi nition of the type of trials that need to be registered, and also of a 20 item "minimal dataset" (outlining 20 characteristics of the trial) that needs to be registered. The project has, in addition, decided to establish a unique identifi er scheme [1] , and to develop a worldwide search portal for trials.
Unfortunately, the pharmaceutical industry arrived at that meeting with an already established position that fi ve items in the minimal dataset are often commercially sensitive. Hence, for some of its trials, the industry proposed to either delay these items' public disclosure or not make them publicly available at all. It proposed instead to allow them to be held in escrow, to be seen by medical journal editors at the time of manuscript evaluation, or just shown to the WHO [2] .
However, even the proposed minimal dataset leaves out many of the crucial items in the Ottawa Statement on principles for trial registration (http:⁄⁄ottawagroup.ohri. ca/statement.html) published by the Ottawa Group, which consists of over 100 individuals and organizations worldwide (http:⁄⁄ottawagroup.ohri. ca/signatories.html).
In this article, I briefl y consider the origins of the global movement for trial registration, and then compare the three different approaches taken by the pharmaceutical industry, the ICTRP, and the Ottawa Group (Table 1) .
Why We Need Trial Registration
The need for trial registration has been recognized for years. However, its urgency became particularly apparent in 2004 with the revelation that trial data on the harms of specifi c serotonin reuptake inhibitors in children went undisclosed [3] . The importance of registering trials has been made clear, for example, by the attorney general of New York's legal action against GlaxoSmithKline [4] , and by the decision of medical journal editors (including the editors of PLoS Medicine and PLoS Clinical Trials) not to publish any trial unless it is has been registered [5] [6] [7] .
Transparency in research and knowledge sharing are now widely seen as a precondition for the success of the health research enterprise. Trial registries are an important tool to help achieve this transparency. Just as research methodology evolved due to advances in technology, so the Internet has made electronic registries entirely feasible. The vision of freely accessible electronic depositories of protocol information of ongoing trials and their results, with each trial assigned a unique number so that it can be tracked, is now achievable.
Trial Registries
Many registries have been developed to meet various specifi c needs. Here I will briefl y present two that have been important in the discussions and decision-making processes of the WHO, the Ottawa Group, and the International Committee of Medical Journal Editors (ICMJE order to participate in them. The US National Institutes of Health, through NLM, has developed this Web site in collaboration with the FDA as a result of the FDA Modernization Act, which was passed into law in November 1997 [8, 9] . Since 2004, and in response to recent intensive international dialogue, each registry has been changing as needed in various ways: expanding their fi elds, becoming publicly owned, or accepting registration of all trials.
The Importance of Knowledge Sharing
Unfortunately, most current ongoing trials are not built on all existing knowledge because all knowledge is not made publicly available-it remains hidden in different pockets by various interested entities. This lack of knowledge sharing is an obstacle to the further creation of knowledge. Even when (some) clinical trial information is shared, the sharing is often delayed until a drug is on the market or, in a somewhat better case, until the trial is published. It typically takes 10-15 years between the initial idea for a trial-formulating and testing the idea, developing a trial protocol, peer reviewing, gaining funding and ethics approval, implementing the trial, developing the consequent intervention (including a drug)-and making it available to those who need it. Thus, we might have to wait up to 15 years to learn about a given trial. However, if the trial is never published, or if further studying is abandoned for whatever reason, this information has a high chance of never being shared.
Such a delay in disclosing ongoing trials means that several different research teams may be studying the same thing simultaneously in isolation, and, hence, are not building on the existing evidence but rather working on a part of the currently available evidence. Precious time and resources are wasted. More importantly, trial participants may be unnecessarily exposed to risk if the substance studied has harmful effects that have not (yet) been disclosed. Above all, research on humans can only be justifi ed if the knowledge arising from that research is made publicly available for the public good. Only by registering trials prospectively can we be sure that all trials that are undertaken are also reported.
International Interest in Trial Registration: The Ottawa Group
Given the importance of knowledge sharing, an international group of those interested in trial registration, including systematic reviewers and pharmaceutical industry representatives, began a dialogue on trial registration in Ottawa, Canada, during the Cochrane Colloquium in October 2004 [10] . This meeting was initiated by the Canadian Institutes of Health Research-a neutral but interested party that has been registering the trials it funds [11] .
The aim of the Ottawa Group dialogue is to discuss and reach global consensus on trial registration, and to understand the meaning of registration for the group members' professional lives, for research, and for medicine and health in general.
The October 2004 meeting led to part I of the Ottawa Statement [10] , summarized in Box 1. The statement has also been translated into and published in Japanese [12] , and other translations are under way. The principles in this statement are simple and clear: disclose the protocol details of all trials up front, disclose amendments along the way, and post the results at the end (http:⁄⁄ottawagroup.ohri.ca/statement. html). Part I was used in the WHOled worldwide consensus building while a dialogue continues, and part II of the statement, which discusses implementation principles, will follow.
The Pharmaceutical Industry's Response
The Ottawa Statement has received endorsements from over 100 individuals and groups on all fi ve continents, but so far there has not been a single signatory from a drug company (the list of signatories is available at http:⁄⁄ottawagroup.ohri. ca/signatories.html). This failure of endorsement by the pharmaceutical industry was unexpected since the Ottawa Statement proposes principles of trial registration, and its endorsement does not mean that any company would need to start implementing these principles immediately and begin registering all details of all trials right away.
The closest that anyone from the pharmaceutical industry has come to endorsing the principles of trial registration are Jesse A. Berlin (Johnson and Johnson) in his commentary, "Why Industry Should Register and Disclose Results of Clinical Studies-Perspective of a Recovering Academic" [13] . While Ronald Krall and Frank Rockhold in their letter, "GSK Has Created Useful Register" [14] , hinted at such a possibility, in a subsequent letter by Krall and Rockhold as a reaction to the publication of part I of the Ottawa Statement, they stated that while "we reiterate our support for the principle of transparency," the authors believed, "there is reason for concern about the amount of detail called for by the Statement" [15] . Both letters refl ect clearly the January 2005 pharmaceutical industry statement [2], reconfi rmed again in September 2005 [16] , and mostly concentrate on the industry's concern about the disclosure of protocol details of early, so-called hypothesis-creating trials.
Although this lack of endorsement by the industry might imply that the Ottawa principles are reaching too far, this is not the case. For example, the minimum set of data items proposed by the Ottawa Statement is already on the electronic National Institute of Health/ NLM ClinicalTrials.gov register, with which the industry is familiar. Rather, this lack of endorsement by the industry explains the fi elds left empty or fi lled in with meaningless information by certain pharmaceutical companies in these registries (D. Zarin [Director of ClinicalTrials.gov], personal communication; [17] ). Using Zarin's analysis in May 2005, the ICMJE stated, "Many entries in the publicly accessible ClinicalTrials.gov database do not provide meaningful information in some key data fi elds," and demanded the validation of registration data [17] . Most current ongoing trials are not built on all existing knowledge.
The WHO ICTRP Minimal Dataset
pharmaceutical companies, and the two major registries, ClinicalTrials.gov and the ISRCTN register. A major outcome of this consultation was the previously mentioned 20 item minimal dataset for trial registration. This dataset has formally been supported by the ICMJE [17] .
However, as mentioned, full up front disclosure of fi ve of these 20 key items is being challenged by the pharmaceutical industry [18] . The fi ve items that industry disagrees with the automatic public disclosure of are the offi cial scientifi c title of the study (item 10), the intervention (item 13), the target sample size (item 17), the primary outcome (item 19), and the key secondary outcomes (item 20). The industry has agreed, instead, to place these fi ve hidden items for an unknown proportion of trials in escrow-that is, into an electronic depository that the public cannot access or will only be able to access with a delay. Table 1 . The document arising from the WHO technical consultation also states that "one or more of data items 10, 13, 17, 19 , 20 may be regarded as sensitive for competitive reasons by the sponsor who may wish to delay release of the information" [18] . However, the WHO's current proposal is that to get registered and obtain a unique identifi cation (ID), all 20 items must be provided to the WHO. Although the ICTRP statement is a great beginning to this WHO project, which aims to be a compromise between the differing positions on public disclosure, the Ottawa Statement should be seen as the goal to which we should aspire.
Why Are All Twenty Items Essential to Understand a Trial?
The pharmaceutical industry claims [1, 16] that a disclosure of one or all fi ve data items would endanger proprietary rights, or as Krall and Rockhold put it, "jeopardize the competitive investment which underlines the creation of new medicines" [15] . But in reality, the lack of public availability of the fi ve key data items raises many problematic issues-for example, it would need to be clear who would approve the reason for withholding a data item from the public or the decision about the eventual timing of disclosure.
The twenty items complement each other, and arguably provide the very minimum dataset needed to understand an ongoing trial. One of these items is the unique ID, nine are administrative, and ten are trial descriptors, the disclosure of fi ve of which are being challenged by the industry. This leaves us with only fi ve trial descriptors as follows: brief title, condition, key inclusion criteria, study type, and recruitment status. Looking at these fi ve items, it becomes clear that they alone are not suffi cient to provide meaningful information about any given trial, and would make trial registration meaningless to the public; i.e., although these data may have been provided to the register and made available to editors, if they are not publicly available, it will be impossible for anyone else to understand the trial. Table 2 illustrates what the description of a trial might look like with the fi ve disputed trial descriptors omitted. For clarity, I also omitted some administrative data items (Table  2) . Evidently, we do not know very much about this trial.
Trial registration has multiple functions, from a registry being a recruitment tool to being a means to fulfi ll legal obligations (I have already mentioned the FDA requirement of registration in case of serious and life-threatening diseases) to broad knowledge sharing, i.e., full disclosure. By mutually complementing each other, full public disclosure of the proposed WHO 20-item minimal registry set would meet all three main functions; without this, registration will not fulfi ll some of these functions. So although, as pointed out by the pharmaceutical industry [19] , these 15 remaining items might seem suffi cient for recruitment of trial participants, they do not meet scientifi c and ethical criteria; hence, all 20 are essential for trial registration.
Conclusion
Knowledge sharing is crucial to health research, and trial registration is an indispensable part of such sharing. It is important that standards for universal trial registration be defi ned and applied globally.
At present, there are clearly major differences among various interested parties concerning which trial characteristics must be made publicly available at registration. As these different parties are all partners and stakeholders in the clinical trials research enterprise, they need to fi nd a compromise between proprietary interests and knowledge sharing. I believe that new ways will have to be developed to protect intellectual and commercial interests and rights, without harming the public interest. There will have to be a change in attitudes to deal with this issue. We have indicated this need for change leading to a new paradigm of health research based on transparency, full disclosure, and collaboration in our earlier paper [10] . We have to keep in mind that although protection of commercial interests is important, the social contract with trial participants must surely take precedence.
As these compromises are worked out, journal editors stand fi rm in their position of requiring a precise trial registration, following the WHO-ICRTP standards. In its effort to move 
